MYCN and Lynch syndrome: These tumors are categorized into three subtypes based on their DNA methylation profiles: RTK1, associated with platelet-derived growth factor receptor alpha (PDGFRA) amplification; tumors with Lynch syndrome or MMR syndrome are also of RTK1 subtype; RTK2, associated with EGFR amplification and telomerase reverse transcriptase (TERT) promoter mutation, and MYCN associated with Myelocytomatosis-N (MYCN) amplification [23,37].